反应详情

The title compound was prepared according to the procedure described in Example 3 (Step b) using tert-butyl 3-[N-((1R)-2-{4-[2-({2-[(tert-butoxy)carbonyl-amino]ethyl}-amino)phenyl]-piperidyl}-1-[(4-chlorophenyl)methyl]-2-oxoethyl)carbamoyl](3S)-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (Step a) (386 mg, 0.5 mmol) and 50% TFA in CH2Cl2 (20 mL). Purification by reverse phase preparative HPLC [Phenomenex; 5 μm 250×21.2 mm, 5% to 95% CH3CN (0.1% TFA) in H2O (0.1% TFA) over 30 min, then 100% CH3CN (0.1% TFA) for 2 min) provided the title compound (TFA salt) as a white foam (162 mg). MS (ESI, pos. ion) m/z: 560 (M+1); (ESI, neg. ion) m/z: 558 (M−1). Calc'd for C32H38ClN5O2: 559.27. Anal. Calcd for C32H38ClN5O2-3C2HF3O2: C, 50.59; H, 4.58; N, 7.76. Found: C, 50.98; H, 4.87; N, 8.01.

1. customThe title compound was prepared
2. customPurification by reverse phase preparative HPLC [Phenomenex